MedCity News November 13, 2024
Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery.
GLP-1 is expected to grow to a $71 billion industry by 2031. GLP-1 medications are fueled by the 66% of Americans who are classified as overweight or obese. No matter what metric, GLP-1 medications total addressable market looks strong, and can reach hundreds of millions just in the US alone.
‘Lose up to 20% of your body weight’, reads an online advertisement. Go anywhere online and you’re sure to find ads offering compounded GLP-1 medications. FDA grants compounding pharmacies temporary approval to compounded medications that are experiencing shortage.
Telehealth...
Today's Sponsors
Today's Sponsor